Anlon Healthcare Limited – Investor Presentation Summary

Key Operational Highlights

  • Portfolio of 142 APIs and pharmaceutical intermediates, led by a core NSAID franchise in propionic-acid (profen) chemistry.
  • 49 products under lab testing (early-stage development), 28 products in pilot stage (scale-up and process validation), and 65 commercialized products in active commercial supply.
  • Total group manufacturing capacity of 1900-2000 MTPA across all entities, with Anlon standalone installed capacity of 400 MTPA.
  • Upcoming capacity expansion of ~1,200 MTPA for Anlon standalone and ~500 MTPA for the group.
  • Key drivers include backward-integrated API manufacturing capabilities, recent acquisitions expanding manufacturing base, and entry into new verticals including formulations, biologics, and medical devices.

Segment-wise Performance

  • The company has evolved from an API-focused manufacturer into an integrated pharmaceutical platform across Industrial & Fine Chemicals → Intermediates → APIs → Formulations → Biologics & Medical Devices.
  • Revenue bifurcation shows a diversified group integrated across the pharma value chain, with Anlon Healthcare maintaining a focused portfolio of niche APIs and intermediates.

Financial Highlights

Q2 FY27 Consolidated Performance (INR Lacs):

  • Revenue from Operations: 10,561.0 (102.3% YoY growth from 5,220.1 in Q2 FY26)
  • Gross Profit: 3,273.5 (70.1% YoY growth)
  • Gross Profit Margin: 31.0% (vs 36.9% in Q2 FY26)
  • EBITDA: 2,524.1 (84.1% YoY growth)
  • EBITDA Margin: 23.9% (vs 26.3% in Q2 FY26)
  • Profit After Tax: 1,717.8 (84.4% YoY growth)
  • PAT Margin: 16.3% (vs 17.8% in Q2 FY26)
  • EPS: 0.32 (vs 0.18 in Q2 FY26)

H1 FY27 Consolidated Performance (INR Lacs):

  • Revenue from Operations: 19,317.2 (125.9% YoY growth from 8,549.9 in H1 FY26)
  • Gross Profit: 5,421.7 (91.5% YoY growth)
  • Gross Profit Margin: 28.1% (vs 33.1% in H1 FY26)
  • EBITDA: 4,083.2 (104.7% YoY growth)
  • EBITDA Margin: 21.1% (vs 23.3% in H1 FY26)
  • Profit After Tax: 2,545.9 (97.9% YoY growth)
  • PAT Margin: 13.2% (vs 15.0% in H1 FY26)
  • EPS: 0.48 (vs 0.24 in H1 FY26)

Drivers of financial performance include significant revenue growth, operational scaling through acquisitions, and expanded manufacturing capabilities. Comparison to market estimates: Not Specified.

Geographical Revenue Split

  • Domestic vs Export/Regional Revenue: Not Specified in quantitative terms
  • The company serves 40+ countries with 125+ customers, with strategic focus on scaling presence in regulated export markets
  • Registered market access includes approvals from PMDA (Japan), NMPA (China), and ANVISA (Brazil)

Balance Sheet Snapshot (Consolidated, Sep-26, INR Lacs)

  • Property, Plant and Equipment: 7,853.0
  • Capital work in progress: 136.2
  • Goodwill: 88.2
  • Inventories: 12,021.1
  • Trade Receivables: 14,275.3
  • Cash and Cash Balances: 725.5
  • Total Assets: 45,271.6
  • Equity Share Capital: 10,630.3
  • Other Equity: 15,109.1
  • Non-Controlling Interests: 3,816.3
  • Total Equity: 29,555.7
  • Short-Term Borrowings: 6,167.3
  • Long-Term Borrowings: 1,061.6
  • Financial Health Insights: Strong asset growth through acquisitions and capacity expansion, increased working capital requirements.

Capex & Cash Flow Health

  • Capital Expenditure: Ongoing expansion with 8 new clean lines commissioning in Q1 FY28 adding roughly 1,200 MTPA capacity
  • Cash Flow from Operating Activities (H1 FY27): -794.3 (negative due to working capital changes of -4,847.1)
  • Cash Flow from Investing Activities: -2,852.5
  • Cash Flow from Financing Activities: 3,935.7
  • Investment Rationale: Focus on capacity expansion, technology upgrades, and vertical integration across the pharmaceutical value chain.

Strategic & R&D Initiatives

  • Investments in Innovation: 4 dedicated R&D laboratories with 11 fume cupboards; zero liquid discharge facility
  • Expansion into new verticals: Peptides & Biosimilars (Anlon Biologics), Surgical Implants (Anlon Medicare), Finished Dosage Formulations (Anlon Medicos)
  • CDMO vertical: Three molecules for two global innovators in development, with validation quantities supplied for Molecule 1
  • Expected impact on growth: CDMO commercialization targeted from Q3 FY27; new formulations and deeper vertical integration to drive growth
  • Strategic Rationale: Expanding into high-growth markets, reducing operational costs through backward integration, and building a complete pharma value chain

Industry Trends & Business Environment

  • Macro/Industry Trends: Global API market growing from USD 144 Bn in 2025 to USD 198 Bn by 2030 (6.6% CAGR); Global NSAIDs market growing from USD 23.8 Bn in 2025 to USD 43.68 Bn by 2034 (6.8% CAGR); India pharma market expected to reach USD 130 Bn by 2030 from USD 60 Bn in FY26
  • Impact on Company: Rising outsourcing trends (73% of novel drug approvals in 2025 involved outsourced API manufacturing), supply chain diversification away from single sourcing, and policy support for import substitution in India creating opportunities for domestic API manufacturers

Management Commentary & Growth Outlook

  • Strategic Outlook: Evolution from API-focused manufacturer to integrated pharmaceutical platform across multiple verticals
  • FY Guidance: 3-5 new DMF filings in FY27; seven new API launches planned across additional therapeutic categories; CDMO commercialisation targeted from Q3 FY27 for Molecule 1 and Q4 FY27 to Q1 FY28 for Molecules 2 & 3
  • Market Share Targets: Not Specified
  • Risks and Opportunities: Regulatory compliance requirements, competition in API manufacturing, and execution of expansion plans

ESG Updates

Not Specified

Digital Transformation

Not Specified